Samsung Biologics Co.,Ltd. (207940.KS), a contract development and manufacturing organization, on Friday reported strong year-on-year growth in profit and revenue for the first quarter.
Net income from continuing operation before income tax rose 45.9% to KRW 640.593 billion from KRW 439.102 billion a year earlier.
Operating income increased to KRW 580.753 billion, compared with KRW 430.240 billion last year.
Net income attributable to shareholders of the parent company came in at KRW 469.245 billion, 41.6% up from KRW 331.333 billion a year earlier.
Sales grew 25.8% to KRW 1.2571 trillion from KRW 999.545 billion in the previous year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.